CD38 and pure red-cell aplasia: SMM-associated PRCA was the leading proposed diagnosis, and a decision was made to start the patient on the CD38-targeting agent daratumumab-hyaluronidase 1800 mg subcutaneous and dexamethasone 40 mg according to clinical standards.